<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04016324</url>
  </required_header>
  <id_info>
    <org_study_id>MDT19002</org_study_id>
    <nct_id>NCT04016324</nct_id>
  </id_info>
  <brief_title>InterStim Basic Evaluation Lead Post-Market Clinical Follow-up Study</brief_title>
  <acronym>BASIC</acronym>
  <official_title>InterStim Basic Evaluation Lead Post Market Clinical Follow-Up Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedtronicNeuro</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedtronicNeuro</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Post-market clinical follow-up for continued assessment of safety and performance of the&#xD;
      InterStim basic evaluation lead and foramen needle(s) used during a therapy evaluation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 28, 2019</start_date>
  <completion_date type="Actual">October 9, 2020</completion_date>
  <primary_completion_date type="Actual">October 6, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>To characterize proportion of subjects who demonstrate motor or sensory response(s) during lead placement using the InterStim Basic Evaluation Lead.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Motor or sensory response(s) during lead placement</measure>
    <time_frame>During lead implant</time_frame>
    <description>To characterize the proportion of subjects who demonstrate motor or sensory response(s) during lead placement using the InterStim basic evaluation lead.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Overactive Bladder</condition>
  <condition>Urinary Urge Incontinence</condition>
  <condition>Urgency-frequency Syndrome</condition>
  <arm_group>
    <arm_group_label>Basic evaluation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects with overactive bladder will go through InterStim basic evaluation with the commercially approved foramen needle and basic evaluation kit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>InterStim Basic Evaluation lead and foramen needle</intervention_name>
    <description>Commercial devices within their intended use as described in approved Instructions for Use.</description>
    <arm_group_label>Basic evaluation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects 18 years of age or older&#xD;
&#xD;
          2. Candidate for sacral neuromodulation in accordance with the InterStim System labeling&#xD;
&#xD;
          3. Have a diagnosis of overactive bladder (OAB) as demonstrated by either urinary urge&#xD;
             incontinence and/or urinary frequency on a 3-day voiding diary&#xD;
&#xD;
          4. Willing and able to accurately complete study diaries, questionnaire, attend visits,&#xD;
             and comply with the study protocol&#xD;
&#xD;
          5. Willing and able to provide signed and dated informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have neurological conditions such as multiple sclerosis, clinically significant&#xD;
             peripheral neuropathy or spinal cord injury (e.g., paraplegia)&#xD;
&#xD;
          2. Have implantable pacemakers, or defibrillators&#xD;
&#xD;
          3. Have primary stress incontinence or mixed incontinence where the stress component&#xD;
             overrides the urge component&#xD;
&#xD;
          4. Have knowledge of planned MRIs, diathermy, microwave exposure, high output ultrasonic&#xD;
             exposure, or radio frequency (RF) energy exposure not included within the scanning&#xD;
             conditions provided with the InterStim System labeling&#xD;
&#xD;
          5. Women who are pregnant or planning to become pregnant during participation in the&#xD;
             study&#xD;
&#xD;
          6. Characteristics indicating a poor understanding of the study or characteristics that&#xD;
             indicate the subject may have poor compliance with the study protocol requirements&#xD;
&#xD;
          7. Concurrent participation in another clinical study that may add additional safety&#xD;
             risks and/or confound study results.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>BASIC Clinical Research Study Team</last_name>
    <role>Study Director</role>
    <affiliation>Medtronic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pinellas Urology</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Urology Partners</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Urology (Plymouth)</name>
      <address>
        <city>Plymouth</city>
        <state>Minnesota</state>
        <zip>55441</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologic Research and Consulting</name>
      <address>
        <city>Englewood</city>
        <state>New Jersey</state>
        <zip>07631</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FirstHealth Urogynecology</name>
      <address>
        <city>Hamlet</city>
        <state>North Carolina</state>
        <zip>28345</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wright State Physicians</name>
      <address>
        <city>Fairborn</city>
        <state>Ohio</state>
        <zip>45234-2640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prisma Health</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605-4627</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Urogynecology</name>
      <address>
        <city>West Columbia</city>
        <state>South Carolina</state>
        <zip>29169-3456</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Partners of North Texas</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology of Virginia</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23642-1815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Urology Associates</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radboud UMC</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Bristol Urological Institute</name>
      <address>
        <city>Bristol</city>
        <zip>BS10 5NB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Newcastle upon Tyne Hospitals</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salford Royal NHS Foundation Trust</name>
      <address>
        <city>Salford</city>
        <zip>M68HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>July 9, 2019</study_first_submitted>
  <study_first_submitted_qc>July 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2019</study_first_posted>
  <last_update_submitted>October 14, 2020</last_update_submitted>
  <last_update_submitted_qc>October 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Overactive Bladder</keyword>
  <keyword>Urinary Urge Incontinence</keyword>
  <keyword>Urgency-frequency Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
    <mesh_term>Urinary Incontinence, Urge</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>October 5, 2021</submitted>
    <returned>November 2, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

